Legislation
SECTION 13-P
Comprehensive prescription drug formulary
Workers' Compensation (WKC) CHAPTER 67, ARTICLE 2
§ 13-p. Comprehensive prescription drug formulary. The chair shall
establish a comprehensive prescription drug formulary on or before
December thirty-first, two thousand seventeen. The prescription drug
formulary shall include a tiered list of high-quality, cost-effective
medications that are pre-approved to be prescribed and dispensed, as
well as additional non-preferred drugs that can be prescribed with prior
approval. Such prescription drug formulary, shall include but not be
limited to implementation of a pharmacy reimbursement strategy,
administration of a prescription drug rebate program for formulary
drugs, a pre-approval program, drug utilization review, and limitations
on the prescribing of compounded medications and compounded topical
preparations. The board shall promulgate regulations to permit an
interested party to submit a request to the medical director of the
board to alter or amend the formulary to consider changing the status of
a drug from non-preferred to preferred. Regulations may include a
provision for reasonable costs and fees associated with the review.
establish a comprehensive prescription drug formulary on or before
December thirty-first, two thousand seventeen. The prescription drug
formulary shall include a tiered list of high-quality, cost-effective
medications that are pre-approved to be prescribed and dispensed, as
well as additional non-preferred drugs that can be prescribed with prior
approval. Such prescription drug formulary, shall include but not be
limited to implementation of a pharmacy reimbursement strategy,
administration of a prescription drug rebate program for formulary
drugs, a pre-approval program, drug utilization review, and limitations
on the prescribing of compounded medications and compounded topical
preparations. The board shall promulgate regulations to permit an
interested party to submit a request to the medical director of the
board to alter or amend the formulary to consider changing the status of
a drug from non-preferred to preferred. Regulations may include a
provision for reasonable costs and fees associated with the review.